Alex Tabarrok points today to an interesting RAND study of prescription drug prices. It turns out that we pay much higher prices than other countries for new, branded drugs, but other countries pay much higher prices for older generics:
But I found this even more interesting:
U.S. prices for brand-name originator drugs were 422 percent of prices in comparison countries, while U.S. unbranded generics, which we found account for 90 percent of U.S. prescription volume, were on average cheaper at 67 percent of prices in comparison countries, where on average only 41 percent of prescription volume is for unbranded generics.
Why do other countries use so few generics? Obviously they have less price pressure to do so since brand-name drugs are relatively cheap compared to the US. But is there more to it? National health care systems could nevertheless reduce drug spending if they pushed generics harder, and it would be low hanging fruit for health systems that are always under budgetary pressure. So why not? Are Europeans just more suspicious of generics than Americans?